Using the expression patterns of only 12 genes from the glycosyltransferase family, we were able to develop a prediction model that forecasts the survival probability of neuroblastoma patients with greater accuracy than the INSS stage, risk status, or MYCN status. The gene discussed is MYCN; the disease is neuroblastoma.